Cancer Research Faces Funding Risks in New Report
The American Association for Cancer Research warns that federal budget cuts and policy changes could stifle medical breakthroughs.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Should the federal government prioritize funding for medical research even during periods of budget cuts?
The American Association for Cancer Research has released a report highlighting a 35% decline in cancer rates since 1991, while warning that federal funding cuts threaten future progress. The report comes as the administration proposes a $5 billion reduction in National Institutes of Health funding for the 2027 fiscal year.
Why it matters
Researchers warn that a $5 billion cut to National Institutes of Health funding, combined with the freezing of 2,200 existing grants, endangers the U.S. position as a global leader in medical innovation. This policy environment threatens to stall efforts to address the 2.1 million new cancer cases expected this year.
Between July 2025 and June 2026, the FDA approved 11 new cancer therapeutics, including dordaviprone to block tumor survival signals. Despite these gains, cancer rates are projected to climb to 2.5 million annual cases by 2050.
The players
American Association for Cancer Research
This professional organization represents researchers and scientists dedicated to the prevention and cure of cancer.
National Institutes of Health
This federal agency is the primary government entity responsible for biomedical and public health research.
National Science Foundation
This federal agency supports fundamental research and education in all the non-medical fields of science and engineering.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
The report highlights both recent medical successes, such as at-home HPV test kits and AI-based imaging tools, and systemic setbacks caused by the administration. Policy shifts have included freezing over 2,200 research grants and removing the board of advisers to the National Science Foundation, moves that researchers fear will reverse decades of scientific progress.
Timeline
Cancer rates declined by 35% between 1991 and 2024.
The administration cut or froze 2,200 NIH research grants in early 2025.
The FDA approved 11 new cancer therapeutics between July 1, 2025, and June 30, 2026.
The President submitted the 2027 fiscal year budget request in April 2026.
A Senate block on grantmaking rules may expire in December 2026.
The Big Picture
This research warning follows the proposed National Institutes of Health fiscal year 2027 budget request, which would fundamentally alter the landscape of federal scientific investment. The report places the current policy trajectory in direct opposition to historical federal research priorities.
Patients may face limited access to new treatments if clinical trials and research grants remain frozen. Future availability of medical innovations like at-home diagnostic tests depends heavily on sustained funding for the agencies developing these technologies.
The takeaway
Advancements in cancer survival depend on consistent federal investment in both basic and clinical research. Patients and providers should monitor funding debates as they directly influence the pace of future therapeutic approvals.
What happens next
A Senate block on specific grantmaking rules is scheduled to expire in December 2026, which may influence the status of frozen research funds.
Further reading
For more on the current state of oncology research, visit Cancer.
Source note: This article includes information reported by Berkeleyside.
Live Poll
Should the federal government prioritize funding for medical research even during periods of budget cuts?
